Other versions:

(Verbatim name)

ID

(Catalog Number)

ORG

DES

Invalid DOI was provided, please try again

XML
PDF
 
 
Twitter
Facebook
Mendeley
Reddit
Notify a colleague
  • ContentsContents
  • Article InfoArticle Info
  • CiteCite
  • MetricsMetrics
  • CommentComment
  • RelatedRelated
  • TabsTabs
  • RefsRefs
  • CitedCited
  • Article title
  • Abstract
  • Keywords
  • Introduction
    • 1. Tumor necrosis factor-α inhibitors (etanercept, adalimumab, infliximab, certolizumab pegol, and golimumab)
      • Etanercept
      • Adalimumab
      • Infliximab
      • Certolizumab pegol
      • Golimumab
    • 2. Interleukin inhibitors (anti-IL)
      • Interleukin-1 (anakinra)
      • Biological products directed against the p40 subunit of IL-12/23
      • IL-17 inhibitors (IL-17i)
      • Interleukin 23 (IL-23)
    • 3. B-cell therapy
      • Anti-B-Ly (Rituximab)
    • 4. T-cell costimulation blocker
  • Conclusion
  • Financing
  • Conflict of interests
  • References
Subscribe to email alerts for current Article's categories
Powered by